16462
2018
eng
preprint
1
2018-07-17
--
--
Pre-therapy Somatostatin-Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy
Purpose: Early identification of aggressive disease could improve decision-support in pancreatic neuroendocrine tumor (pNET) patients prior to peptide receptor radionuclide therapy (PRRT). The prognostic value of intratumoral textural features (TF) determined by baseline somatostatin receptor (SSTR)-PET before PRRT was analyzed.
Procedures: 31 patients with G1/G2 pNET were enrolled (G2, n=23/31). Prior to PRRT with [\(^{177}\)Lu]DOTATATE (mean, 3.6 cycles), baseline SSTR-PET/CT was performed. By segmentation of 162 (median per patient, 5) metastases, intratumoral TF were computed. The impact of conventional PET parameters (SUV\(_{mean/max}\)), imaging-based TF as well as clinical parameters (Ki67, CgA) for prediction of both progression-free (PFS) and overall survival (OS) after PRRT was evaluated.
Results: Within a median follow-up of 3.7y, tumor progression was detected in 21 patients (median, 1.5y) and 13/31 deceased (median, 1.9y). In ROC analysis, the TF Entropy, reflecting derangement on a voxel-by-voxel level, demonstrated predictive capability for OS (cutoff=6.7, AUC=0.71, p=0.02). Of note, increasing Entropy could predict a longer survival (>6.7, OS=2.5y, 17/31), whereas less voxel-based derangement portended inferior outcome (<6.7, OS=1.9y, 14/31). These findings were supported in a G2 subanalysis (>6.9, OS=2.8y, 9/23 vs. <6.9, OS=1.9y, 14/23). Kaplan-Meier analysis revealed a significant distinction between high- and low-risk groups using Entropy (n=31, p<0.05). For those patients below the ROC-derived threshold, the relative risk of death after PRRT was 2.73 (n=31, p=0.04). Ki67 was negatively associated with PFS (p=0.002); however, SUVmean/max failed in prognostication (n.s.).
Conclusions: In contrast to conventional PET parameters, assessment of intratumoral heterogeneity demonstrated superior prognostic performance in pNET patients undergoing PRRT. This novel PET-based strategy of outcome prediction prior to PRRT might be useful for patient risk stratification.
Molecular Imaging and Biology
https://doi.org/10.1007/s11307-018-1252-5
https://link.springer.com/article/10.1007/s11307-018-1252-5
1536-1632
urn:nbn:de:bvb:20-opus-164624
This is a post-peer-review, pre-copyedit version of an article published in Molecular Imaging and Biology. The final authenticated version is available online at: http://dx.doi.org/s11307-018-1252-5
Die finale Version dieses Artikels steht unter https://doi.org/10.1007/s11307-018-1252-5 bzw. http://nbn-resolving.org/urn:nbn:de:bvb:20-opus-167168 open access zur Verfügung.
Johns Hopkins School of Medicine
Molecular Imaging and Biology (2018). https://doi.org/10.1007/s11307-018-1252-5
701983
Deutsches Urheberrecht
Rudolf A. Werner
Harun Ilhan
Sebastian Lehner
László Papp
Norbert Zsótér
Imke Schatka
Dirk O. Muegge
Mehrbod S. Javadi
Takahiro Higuchi
Andreas K. Buck
Peter Bartenstein
Frank Bengel
Markus Essler
Constantin Lapa
Ralph A. Bundschuh
eng
uncontrolled
Pancreas
deu
swd
Positronen-Emissions-Tomografie
eng
uncontrolled
PET
eng
uncontrolled
neuroendocrine tumor
eng
uncontrolled
tumor heterogeneity
eng
uncontrolled
[68Ga]
eng
uncontrolled
[177Lu]-DOTATATE/-DOTATOC
eng
uncontrolled
PET/CT
eng
uncontrolled
SSTR
Medizin und Gesundheit
open_access
Klinik und Poliklinik für Nuklearmedizin
OpenAIRE
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/16462/Werner_Radiomics_Molecular_Imaging_Biology_accepted_version.pdf
15800
2017
eng
1489-1498
6
7
article
1
2018-02-23
--
--
Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach
C-X-C motif chemokine receptor 4 (CXCR4) and somatostatin receptors (SSTR) are overexpressed in gastro-entero-pancreatic neuroendocrine tumors (GEP-NET). In this study, we aimed to elucidate the feasibility of non-invasive CXCR4 positron emission tomography/computed tomography (PET/CT) imaging in GEP-NET patients using [\(^{68}\)Ga]Pentixafor in comparison to \(^{68}\)Ga-DOTA-D-Phe-Tyr3-octreotide ([\(^{68}\)Ga]DOTATOC) and \(^{18}\)F-fluorodeoxyglucose ([\(^{18}\)F]FDG). Twelve patients with histologically proven GEP-NET (3xG1, 4xG2, 5xG3) underwent [\(^{68}\)Ga]DOTATOC, [\(^{18}\)F]FDG, and [\(^{68}\)Ga]Pentixafor PET/CT for staging and planning of the therapeutic management. Scans were analyzed on a patient as well as on a lesion basis and compared to immunohistochemical staining patterns of CXCR4 and somatostatin receptors SSTR2a and SSTR5. [\(^{68}\)Ga]Pentixafor visualized tumor lesions in 6/12 subjects, whereas [\(^{18}\)F]FDG revealed sites of disease in 10/12 and [\(^{68}\)Ga]DOTATOC in 11/12 patients, respectively. Regarding sensitivity, SSTR-directed PET was the superior imaging modality in all G1 and G2 NET. CXCR4-directed PET was negative in all G1 NET. In contrast, 50% of G2 and 80% of G3 patients exhibited [\(^{68}\)Ga]Pentixafor-positive tumor lesions. Whereas CXCR4 seems to play only a limited role in detecting well-differentiated NET, increasing receptor expression could be non-invasively observed with increasing tumor grade. Thus, [\(^{68}\)Ga]Pentixafor PET/CT might serve as non-invasive read-out for evaluating the possibility of CXCR4-directed endoradiotherapy in advanced dedifferentiated SSTR-negative tumors.
Theranostics
10.7150/thno.18754
urn:nbn:de:bvb:20-opus-158008
Theranostics 2017; 7(6): 1489-1498. doi: 10.7150/thno.18754
701983
CC BY-NC: Creative-Commons-Lizenz: Namensnennung, Nicht kommerziell 4.0 International
Rudolf A. Werner
Alexander Weich
Takahiro Higuchi
Jan S. Schmid
Andreas Schirbel
Michael Lassmann
Vanessa Wild
Martina Rudelius
Theodor Kudlich
Ken Herrmann
Michael Scheurlen
Andreas K. Buck
Saskia Kropf
Hans-Jürgen Wester
Constantin Lapa
eng
uncontrolled
SSTR
eng
uncontrolled
peptide receptor radionuclide therapy
eng
uncontrolled
neuroendocrine tumor
eng
uncontrolled
[\(^{68}\)Ga]Pentixafor
eng
uncontrolled
CXCR4
eng
uncontrolled
chemokine receptor
eng
uncontrolled
PET/CT
eng
uncontrolled
DOTATOC
eng
uncontrolled
PRRT
deu
swd
Positronen-Emissions-Tomografie
Medizin und Gesundheit
open_access
Klinik und Poliklinik für Nuklearmedizin
Pathologisches Institut
Medizinische Klinik und Poliklinik II
OpenAIRE
Förderzeitraum 2017
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/15800/Werner_Theranostics.pdf
17731
2016
eng
41233-41241
27
7
article
1
2019-02-26
--
--
The impact of \(^{177}\)Lu-octreotide therapy on \(^{99m}\)Tc-MAG3 clearance is not predictive for late nephropathy
Peptide Receptor Radionuclide Therapy (PRRT) for the treatment of neuroendocrine tumors may lead to kidney deterioration. This study aimed to evaluate the suitability of \(^{99m}\)Tc-mercaptoacetyltriglycine (\(^{99m}\)Tc-MAG3) clearance for the early detection of PRRT-induced changes on tubular extraction (TE). TE rate (TER) was measured prior to 128 PRRT cycles (7.6±0.4 GBq \(^{177}\)Lu-octreotate/octreotide each) in 32 patients. TER reduction during PRRT was corrected for age-related decrease and analyzed for the potential to predict loss of glomerular filtration (GF). The GF rate (GFR) as measure for renal function was derived from serum creatinine. The mean TER was 234 ± 53 ml/min/1.73 m² before PRRT (baseline) and 221 ± 45 ml/min/1.73 m² after a median follow-up of 370 days. The age-corrected decrease (mean: -3%, range: -27% to +19%) did not reach significance (p=0.09) but significantly correlated with the baseline TER (Spearman p=-0.62, p<0.001). Patients with low baseline TER showed an improved TER after PRRT, high decreases were only observed in individuals with high baseline TER. Pre-therapeutic TER data were inferior to plasma creatinine-derived GFR estimates in predicting late nephropathy. TER assessed by \(^{99m}\)Tc-MAG3clearance prior to and during PRRT is not suitable as early predictor of renal injury and an increased risk for late nephropathy.
Oncotarget
10.18632/oncotarget.9775
urn:nbn:de:bvb:20-opus-177318
Oncotarget 2016, 7:27, 41233-41241. DOI: 10.18632/oncotarget.9775
false
true
Rudolf A. Werner
Seval Beykan
Takahiro Higuchi
Katharina Lückerath
Alexander Weich
Michael Scheurlen
Christina Bluemel
Ken Herrmann
Andreas K. Buck
Michael Lassmann
Constantin Lapa
Heribert Hänscheid
eng
uncontrolled
renal scintigraphy
eng
uncontrolled
neuroendocrine tumor
eng
uncontrolled
177Lu
eng
uncontrolled
MAG3
eng
uncontrolled
PRRT
Pharmakologie, Therapeutik
open_access
Klinik und Poliklinik für Nuklearmedizin
Medizinische Klinik und Poliklinik II
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/17731/Werner_Oncotarget.pdf
16716
2018
eng
article
1
2018-08-16
--
--
Pre-therapy Somatostatin-Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy
Purpose: Early identification of aggressive disease could improve decision-support in pancreatic neuroendocrine tumor (pNET) patients prior to peptide receptor radionuclide therapy (PRRT). The prognostic value of intratumoral textural features (TF) determined by baseline somatostatin receptor (SSTR)-PET before PRRT was analyzed.
Procedures: 31 patients with G1/G2 pNET were enrolled (G2, n=23/31). Prior to PRRT with [\(^{177}\)Lu]DOTATATE (mean, 3.6 cycles), baseline SSTR-PET/CT was performed. By segmentation of 162 (median per patient, 5) metastases, intratumoral TF were computed. The impact of conventional PET parameters (SUV\(_{mean/max}\)), imaging-based TF as well as clinical parameters (Ki67, CgA) for prediction of both progression-free (PFS) and overall survival (OS) after PRRT was evaluated.
Results: Within a median follow-up of 3.7y, tumor progression was detected in 21 patients (median, 1.5y) and 13/31 deceased (median, 1.9y). In ROC analysis, the TF Entropy, reflecting derangement on a voxel-by-voxel level, demonstrated predictive capability for OS (cutoff=6.7, AUC=0.71, p=0.02). Of note, increasing Entropy could predict a longer survival (>6.7, OS=2.5y, 17/31), whereas less voxel-based derangement portended inferior outcome (<6.7, OS=1.9y, 14/31). These findings were supported in a G2 subanalysis (>6.9, OS=2.8y, 9/23 vs. <6.9, OS=1.9y, 14/23). Kaplan-Meier analysis revealed a significant distinction between high- and low-risk groups using Entropy (n=31, p<0.05). For those patients below the ROC-derived threshold, the relative risk of death after PRRT was 2.73 (n=31, p=0.04). Ki67 was negatively associated with PFS (p=0.002); however, SUVmean/max failed in prognostication (n.s.).
Conclusions: In contrast to conventional PET parameters, assessment of intratumoral heterogeneity demonstrated superior prognostic performance in pNET patients undergoing PRRT. This novel PET-based strategy of outcome prediction prior to PRRT might be useful for patient risk stratification.
Molecular Imaging and Biology
10.1007/s11307-018-1252-5
1536-1632
urn:nbn:de:bvb:20-opus-167168
Molecular Imaging and Biology (2018) DOI: 10.1007/s11307-018-1252-5
701983
Johns Hopkins School of Medicine
CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International
Rudolf A. Werner
Harun Ilhan
Sebastian Lehner
László Papp
Norbert Zsótér
Imke Schatka
Dirk O. Muegge
Mehrbod S. Javadi
Takahiro Higuchi
Andreas K. Buck
Peter Bartenstein
Frank Bengel
Markus Essler
Constantin Lapa
Ralph A. Bundschuh
eng
uncontrolled
tumor heterogeneity
deu
swd
Positronen-Emissions-Tomografie
eng
uncontrolled
PET
eng
uncontrolled
PET/CT
eng
uncontrolled
pancreas
eng
uncontrolled
SSTR
eng
uncontrolled
[177Lu]-DOTATATE/-DOTATOC
eng
uncontrolled
[68Ga]
eng
uncontrolled
neuroendocrine tumor
Medizin und Gesundheit
open_access
Klinik und Poliklinik für Nuklearmedizin
OpenAIRE
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/16716/Werner_Pre-therapySomatostatinReceptor_MIB_2018.pdf
16699
2018
eng
article
1
2018-08-10
--
--
MI-RADS: Molecular Imaging Reporting and Data Systems – A Generalizable Framework for Targeted Radiotracers with Theranostic Implications
Both prostate-specific membrane antigen (PSMA)- and somatostatin receptor (SSTR)-targeted positron emission tomography (PET) imaging agents for staging and restaging of prostate carcinoma or neuroendocrine tumors, respectively, are seeing rapidly expanding use. In addition to diagnostic applications, both classes of radiotracers can be used to triage patients for theranostic endoradiotherapy. While interpreting PSMA- or SSTR-targeted PET/computed tomography (CT) scans, the reader has to be aware of certain pitfalls. Adding to the complexity of the interpretation of those imaging agents, both normal biodistribution, and also false-positive and -negative findings differ between PSMA- and SSTR-targeted PET radiotracers. Herein summarized under the umbrella term molecular imaging reporting and data systems (MI-RADS), two novel RADS classifications for PSMA- and SSTR-targeted PET imaging are described (PSMA- and SSTR-RADS). Both framework systems may contribute to increase the level of a reader’s confidence and to navigate the imaging interpreter through indeterminate lesions, so that appropriate workup for equivocal findings can be pursued. Notably, PSMA- and SSTR-RADS are structured in a reciprocal fashion, i.e. if the reader is familiar with one system, the other system can readily be applied as well. In the present review we will discuss the most common pitfalls on PSMA- and SSTR-targeted PET/CT, briefly introduce PSMA- and SSTR-RADS, and define a future role of the umbrella framework MI-RADS compared to other harmonization systems.
Annals of Nuclear Medicine
0914-7187
urn:nbn:de:bvb:20-opus-166995
10.1007/s12149-018-1291-7
Johns Hopkins School of Medicine
Annals of Nuclear Medicine (2018). https://doi.org/10.1007/s12149-018-1291-7
701983
CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International
Rudolf A. Werner
Ralph A. Bundschuh
Lena Bundschuh
Mehrbod S. Javadi
Takahiro Higuchi
Alexander Weich
Sara Sheikhbahaei
Kenneth J. Pienta
Andreas K. Buck
Martin G. Pomper
Michael A. Gorin
Constantin Lapa
Steven P. Rowe
eng
uncontrolled
PET
deu
swd
Positronen-Emissions-Tomografie
eng
uncontrolled
prostate cancer
eng
uncontrolled
neuroendocrine tumor
eng
uncontrolled
prostate-specific membrane antigen (PSMA)
eng
uncontrolled
somatostatin receptor (SSTR)
eng
uncontrolled
positron emission tomography
eng
uncontrolled
theranostics
eng
uncontrolled
standardization
eng
uncontrolled
RADS
eng
uncontrolled
reporting and data systems
eng
uncontrolled
personalized medicine
Medizin und Gesundheit
open_access
Klinik und Poliklinik für Nuklearmedizin
Medizinische Klinik und Poliklinik II
OpenAIRE
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/16699/Werner_MI-RDAS_Annals_Nuclear_Medicine_2018.pdf
17026
2018
eng
6088-6100
22
8
article
1
2018-10-26
--
--
The theranostic promise for neuroendocrine tumors in the late 2010s – Where do we stand, where do we go?
More than 25 years after the first peptide receptor radionuclide therapy (PRRT), the concept of somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors (NET) is seeing rapidly increasing use. To maximize the full potential of its theranostic promise, efforts in recent years have expanded recommendations in current guidelines and included the evaluation of novel theranostic radiotracers for imaging and treatment of NET. Moreover, the introduction of standardized reporting framework systems may harmonize PET reading, address pitfalls in interpreting SSTR-PET/CT scans and guide the treating physician in selecting PRRT candidates. Notably, the concept of PRRT has also been applied beyond oncology, e.g. for treatment of inflammatory conditions like sarcoidosis. Future perspectives may include the efficacy evaluation of PRRT compared to other common treatment options for NET, novel strategies for closer monitoring of potential side effects, the introduction of novel radiotracers with beneficial pharmacodynamic and kinetic properties or the use of supervised machine learning approaches for outcome prediction. This article reviews how the SSTR-directed theranostic concept is currently applied and also reflects on recent developments that hold promise for the future of theranostics in this context.
Theranostics
urn:nbn:de:bvb:20-opus-170264
Johns Hopkins School of Medicine
Theranostics 2018; 8(22):6088-6100. doi:10.7150/thno.30357
701983
CC BY-NC: Creative-Commons-Lizenz: Namensnennung, Nicht kommerziell 4.0 International
Rudolf A. Werner
Alexander Weich
Malte Kircher
Lilja B. Solnes
Mehrbod S. Javadi
Takahiro Higuchi
Andreas K. Buck
Martin G. Pomper
Steven Rowe
Constantin Lapa
eng
uncontrolled
theranostics
deu
swd
Positronen-Emissions-Tomografie
eng
uncontrolled
PRRT
eng
uncontrolled
somatostatin receptor
eng
uncontrolled
peptide receptor radionuclide therapy
eng
uncontrolled
neuroendocrine tumor
Medizin und Gesundheit
open_access
Klinik und Poliklinik für Nuklearmedizin
Medizinische Klinik und Poliklinik II
OpenAIRE
Förderzeitraum 2018
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/17026/Werner_Theranostics_2018.pdf
17028
2018
eng
1-9
article
1
2018-10-27
--
--
Impact of Tumor Burden on Quantitative [\(^{68}\)Ga]DOTATOC Biodistribution
Purpose: As has been previously reported, the somatostatin receptor (SSTR) imaging agent [\(^{68}\)Ga]-labeled 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-d-Phe(1)-Tyr(3)-octreotate ([\(^{68}\)Ga]DOTATATE) demonstrates lower uptake in normal organs in patients with a high neuroendocrine tumor (NET) burden. Given the higher SSTR affinity of [\(^{68}\)Ga]DOTATATE, we aimed to quantitatively investigate the biodistribution of [\(^{68}\)Ga]-labeled 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-d-Phe(1)-Tyr(3)-octreotide ([68Ga]DOTATOC) to determine a potential correlation between uptake in normal organs and NET burden.
Procedures: Of the 44 included patients, 36/44 (82%) patients demonstrated suspicious radiotracer uptake on [\(^{68}\)Ga]DOTATOC positron emission tomography (PET)/x-ray computed tomography (CT). Volumes of Interest (VOIs) were defined for tumor lesions and normal organs (spleen, liver, kidneys, adrenals). Mean body weight corrected standardized uptake value (SUV\(_{mean}\)) for normal organs was assessed and was used to calculate the corresponding mean specific activity uptake (Upt: fraction of injected activity per kg of tissue). For the entire tumor burden, SUV\(_{mean}\), maximum standardized uptake value (SUV\(_{max}\)), and the total mass (TBM) was calculated and the decay corrected tumor fractional uptake (TBU) was assessed. A Spearman’s rank correlation coefficient was used to determine the correlations between normal organ uptake and tumor burden.
Results: The median SUV\(_{mean}\) was 18.7 for the spleen (kidneys, 9.2; adrenals, 6.8; liver, 5.6). For tumor burden, the median values were SUV\(_{mean}\) 6.9, SUV\(_{max}\) 35.5, TBM 42.6g, and TBU 1.2%. With increasing volume of distribution, represented by lean body mass and body surface area (BSA), Upt decreased in kidneys, liver, and adrenal glands and SUV\(_{mean}\) increased in the spleen. Correlation improved only for both kidneys and adrenals when the influence of the tumor uptake on the activity available for organ uptake was taken into account by the factor 1/(1-TBU). TBU was neither predictive for SUV\(_{mean}\) nor for Upt in any of the organs. The distribution of organ Upt vs. BSA/(1-TBU) were not different for patients with minor TBU (<3%) vs. higher TBU (>7%), indicating that the correlations observed in the present study are explainable by the body size effect. High tumor mass and uptake mitigated against G1 NET.
Conclusions: There is no significant impact on normal organ biodistribution with increasing tumor burden on [\(^{68}\)Ga]DOTATOC PET/CT. Potential implications include increased normal organ dose with [\(^{177}\)Lu-DOTA]\(^0\)-D-Phe\(^1\)-Tyr\(^3\)-Octreotide and decreased absolute lesion detection with [\(^{68}\)Ga]DOTATOC in high NET burden.
Molecular Imaging and Biology
urn:nbn:de:bvb:20-opus-170280
Johns Hopkins School of Medicine
Molecular Imaging and Biology (2018). https://doi.org/10.1007/s11307-018-1293-9
701983
CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International
Rudolf Werner
Heribert Hänscheid
Jeffrey P. Leal
Mehrbod S. Javadi
Takahiro Higuchi
Martin A. Lodge
Andreas K. Buck
Martin G. Pomper
Constantin Lapa
Steven P. Rowe
eng
uncontrolled
somatostatin receptor
deu
swd
Positronen-Emissions-Tomografie
eng
uncontrolled
quantification
eng
uncontrolled
[68Ga]DOTATOC
eng
uncontrolled
neuroendocrine tumor
eng
uncontrolled
SSTR-PET
eng
uncontrolled
theranostics
Medizin und Gesundheit
open_access
Klinik und Poliklinik für Nuklearmedizin
OpenAIRE
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/17028/Rudolf_Werner_MIB_2018_ImpactOfTumorBurden.pdf
32464
2022
eng
631-640
4
24
article
1
--
--
--
Training on reporting and data system (RADS) for somatostatin-receptor targeted molecular imaging can reduce the test anxiety of inexperienced readers
Purpose
For somatostatin receptor (SSTR)-positron emission tomography/computed tomography (PET/CT), a standardized framework termed SSTR-reporting and data system (RADS) has been proposed. We aimed to elucidate the impact of a RADS-focused training on reader’s anxiety to report on SSTR-PET/CT, the motivational beliefs in learning such a system, whether it increases reader’s confidence, and its implementation in clinical routine.
Procedures
A 3-day training course focusing on SSTR-RADS was conducted. Self-report questionnaires were handed out prior to the course (Pre) and thereafter (Post). The impact of the training on the following categories was evaluated: (1) test anxiety to report on SSTR-PET/CT, (2) motivational beliefs, (3) increase in reader’s confidence, and (4) clinical implementation. To assess the effect size of the course, Cohen’s d was calculated (small, d = 0.20; large effect, d = 0.80).
Results
Of 22 participants, Pre and Post were returned by 21/22 (95.5%). In total, 14/21 (66.7%) were considered inexperienced (IR, < 1 year experience in reading SSTR-PET/CTs) and 7/21 (33.3%) as experienced readers (ER, > 1 year). Applying SSTR-RADS, a large decrease in anxiety to report on SSTR-PET/CT was noted for IR (d = − 0.74, P = 0.02), but not for ER (d = 0.11, P = 0.78). For the other three categories motivational beliefs, reader’s confidence, and clinical implementation, agreement rates were already high prior to the training and persisted throughout the course (P ≥ 0.21).
Conclusions
A framework-focused reader training can reduce anxiety to report on SSTR-PET/CTs, in particular for inexperienced readers. This may allow for a more widespread adoption of this system, e.g., in multicenter trials for better intra- and interindividual comparison of scan results.
Molecular Imaging and Biology
10.1007/s11307-022-01712-6
urn:nbn:de:bvb:20-opus-324645
@articleWeich.2022, author = Weich, Alexander and Higuchi, Takahiro and Bundschuh, Ralph A. and Lapa, Constantin and Serfling, Sebastian E. and Rowe, Steven P. and Pomper, Martin G. and Herrmann, Ken and Buck, Andreas K. and Derlin, Thorsten and Werner, Rudolf A., year = 2022, title = Training on Reporting and Data System (RADS) for Somatostatin-Receptor Targeted Molecular Imaging Can Reduce the Test Anxiety of Inexperienced Readers, pages = 631–640, volume = 24, number = 4, journal = Molecular imaging and biology, doi = 10.1007/s11307-022-01712-6
md5:cbf6bcfa88ba2960624db078d2f727c9
2023-08-12T10:37:25+00:00
/tmp/phpKtPjJc
bibtex
64d760e520e2f0.54800151
Molecular Imaging and Biology (2022) 24:4, 631-640. DOI: 10.1007/s11307-022-01712-6
false
true
CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International
Alexander Weich
Takahiro Higuchi
Ralph A. Bundschuh
Constantin Lapa
Sebastian E. Serfling
Steven P. Rowe
Martin G. Pomper
Ken Herrmann
Andreas K. Buck
Thorsten Derlin
Rudolf A. Werner
eng
uncontrolled
PET/CT
eng
uncontrolled
neuroendocrine tumor
eng
uncontrolled
PRRT
eng
uncontrolled
peptide receptor radionuclide therapy
eng
uncontrolled
reporting and data system
eng
uncontrolled
SSTR-RADS
eng
uncontrolled
RADS
Medizin und Gesundheit
open_access
Klinik und Poliklinik für Nuklearmedizin
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/32464/s11307-022-01712-6.pdf